Similar Articles

  • The Hypertension Optimal Treatment Trial

    Donald G. Vidt, MD and Marc A. Pohl, MD
    • Cleveland Clinic Journal of Medicine February 1999, 66 (2) 105-111;

    • In hypertensive patients, low-dose aspirin proves beneficial, but more-aggressive blood pressure treatment falls short—except in persons with diabetes.

  • Should catheter ablation be the first line of treatment for atrial fibrillation?

    Bruce D. Lindsay, MD
    • Cleveland Clinic Journal of Medicine September 2009, 76 (9) 503-506;
    • DOI: https://doi.org/10.3949/ccjm.76a.09070

    • Antiarrhythmic drugs should remain the first line of treatment until trials prove otherwise.

  • Parenteral Fluid Therapy

    R. H. McDonald, M.D
    • Cleveland Clinic Journal of Medicine April 1946, 13 (2) 96-103;

  • A drug, a concept, and a clinical trial on trial

    Brian F. Mandell, MD, PhD
    • Cleveland Clinic Journal of Medicine July 2008, 75 (7) 470;

    • The ENHANCE trial, evaluating the addition of a second hypocholesterolemic drug (ezetimibe) to a statin using two surrogate end points in a relatively small number of patients, hit the national news when the two surrogates didn’t match up.

  • Catheter ablation: a ‘charge’ into the future

    Richard G. Trohman, MD and Anita Zeiler Arnold, DO
    • Cleveland Clinic Journal of Medicine May 1991, 58 (3) 218-220;

  • A Snapshot Survey of Fluid Prescribing

    Helen Grote, MD, Luke Evans, MRCS, Abdel Omer, MD, PhD, FRCS and Rob Lewis, MD, FRCA
    • Cleveland Clinic Journal of Medicine March 2010, 77 (3 esuppl 1) eS29;

  • The ALLHAT Trial

    Donald G. Vidt, MD
    • Cleveland Clinic Journal of Medicine March 2003, 70 (3) 263-269;

    • Diuretics are unsurpassed in lowering blood pressure, reducing clinical events, tolerability, and low cost.

  • The ACUTE Trial

    Craig R. Asher, MD and Allan L. Klein, MD
    • Cleveland Clinic Journal of Medicine September 2002, 69 (9) 713-718;

    • A TEE-guided approach showed no advantage over conventional management in rates of embolic events, but shortened the anticoagulation course, allowed for earlier cardioversion, and caused fewer bleeding events.

  • The Mustt Trial

    Stephen Pavia, MD and Bruce L. Wilkoff, MD
    • Cleveland Clinic Journal of Medicine February 2001, 68 (2) 113-129;

    • Implantable defibrillators, but not antiarrhythmic drugs reduce the mortality rate in MI survivors at high risk.

  • The HIP trial

    Chad L. Deal, MD
    • Cleveland Clinic Journal of Medicine December 2002, 69 (12) 964-976;

    • Patients should be selected for bisphosphonate therapy on the basis of low bone density, not age.

Previous
Next